Accelevir Diagnostics

Throwback to the Crab Trap: Celebrating Cerillo’s Innovation in Microbiome Research BioHealth Innovation, Inc. (BHI) led another great year of the 10th Annual BioHealth Capital Region Forum and the 9th Annual Crab Trap Competition. Accelevir Diagnostics is thrilled to celebrate Cerillo, a Charlottesville, VA-based company, who earned $10,000 in CRO services, sponsored by both Accelevir Diagnostics and Noble Life Sciences Inc, said Albine Martin, PhD, Co-Founder and Managing Director of Accelevir Diagnostics, who also served as a Crab Trap judge. “The Crab Trap is an incredible platform for showcasing innovation, and we are thrilled to support Cerillo as they work to advance microbiome research. Congratulations to Eric and the Cerillo team—we’re excited to partner with you on this important journey.” She further noted, "It takes a village," and this year's BioHealth Capital Region Forum continues to highlight the momentum and collaboration opportunities to support companies within our community.

Uncover Anti-Drug Antibodies - Explore Accelevir Diagnostics' #immunogenicity testing services, including assays for anti-drug and neutralizing #antibodies (#NAb). #ImmunogenicityTesting #TherapeuticResearch #NeutralizingAntibodies 🌐 Learn more at https://lnkd.in/eha7qVYP

Accelevir Diagnostics' ELISpot and FluoroSpot services detect T and B cell targets for multiple species. #TCellResearch #BCellAssays #Immunology 🧪 Discover more at https://lnkd.in/eha7qVYP

Accelevir Diagnostics provides assays for lymphokines and chemokines with current offerings like #HIV-1 P24 and LAg-avidity. Discover the potential for rapid expansion. #BiomarkerAnalysis #InfectiousDisease #AssayDevelopment 🔍 Learn more at https://lnkd.in/eha7qVYP

Expand Your Research Potential Learn about Accelevir Diagnostics' quantitative assays for protein analysis, including #HIV-1 P24 and LAg-avidity. Accelevir's offerings can expand to various human, rodent, NHP, and pig protein targets. #QuantitativeAssays #ProteinAnalysis #InfectiousDiseaseResearch ➡️ Find out more at https://lnkd.in/eha7qVYP

💡 Conserved patterns, global solutions At the heart of #HIV-1 cure research is the ability to distinguish between intact and defective proviruses. Dr. Hannah MacLeod’s latest work, presented at #CROI2024, highlights AccelevirDx’s advances in #sequencing technology, showing consistent proviral landscapes across Group M. This research supports the global application of IPDA® Version 2, driving us closer to a unified HIV-1 cure effort. 📍 Learn more about her cutting-edge findings https://bit.ly/3TghsBT

📅 Join us at "HIV in 2024: Progress, Problems, and Prospects,” hosted by Hood College in partnership with Frederick National Laboratory for Cancer Research, September 23-25 in Frederick, Maryland. Explore the latest in HIV/AIDS research with esteemed experts. Topics include next-gen vaccine design and delivery approaches, molecular aspects of the HIV reservoir, CNS infections with HIV and more: hood.ws/hivs-2024 #HIVS2024

Exciting to see Albine Martin representing Accelevir Diagnostics on the #BHCR entrepreneur's panel today! BioHealth Innovation, Inc. #entrepreneurs #biohealthweek #maryland

Together, Accelevir Diagnostics and Noble Life Sciences Inc Sciences are attending the 10th Annual BioHealth Capital Region Forum this week!     Albine Martin, Greg Laird, Kenneth Carter, Denny Snyder, Yongping Chen (CRO, Oncology, Infectious Diseases, Cell & Gene Therapy), and Haimi Shiferaw will be attending the Forum this week and the Crab Trap Pitch Competition on the 18th.     🦀 We are proud to help sponsor this year's Crab Trap Competition, and we look forward to hearing the finalist's pitch today. We're excited to see who will win this year's event!     Learn more about this event: https://lnkd.in/e4UP-R3u    BioHealth Innovation, Inc. BioHealth Capital Region   #biohealth #biotech #maryland #lifesciences #biopharma #BHCR #crabtrap #biotechindustry 

🧬 Can sequencing revolutionize #HIV-1 cure research? Dr. Hannah MacLeod’s poster at #CROI2024 unveils new discoveries in HIV-1 provirus analysis across major Group M subtypes. Utilizing AccelevirDx’s innovative single-genome sequencing assay, the study demonstrates critical conserved patterns in proviral defects—findings that could shape the future of global HIV-1 cure strategies. 🚀 📊 Dive deeper into the research and how it supports the development of IPDA® Version 2: https://bit.ly/3TghsBT